Trusted News Discovery Since 2008
One News Page
One News Page > Business News > VolitionRx unveils new epigenetic toolbox off new research into Nu.Q Capture program

VolitionRx unveils new epigenetic toolbox off new research into Nu.Q Capture program

Proactive Investors Tuesday, 18 February 2020
VolitionRx Limited (NYSEAMERICAN:VNRX) is unveiling a new epigenetic toolbox thanks to new research on its Nu.Q Capture program.  The Austin, Texas-based company said Tuesday that research on its Nu.Q program led to the development of a suite of novel epigenetic tools for cancer diagnostics.  The research builds upon breakthroughs on Volition’s assay platform that it announced last month.  READ: VolitionRx introduces new magnetic particle-based Nu.Q assay format The new tools could usher in a paradigm shift in epigenetic-based blood tests, according to Dr Mark Eccleston, one of Volition’s founding scientists and its business development director. Eccleston also told shareholders that the tools will help Volition establish a leadership position in the epigenetics diagnostics field.  Nu.Q Capture technologies have emanated from years of focused research in clinical epigenetics, Volition’s chief scientific officer Dr Jake Micallef told shareholders.   “We have filed several patents relating to these Nu.Q methods to add to Volition's already extensive patent portfolio, with the aim of securing broad coverage and protection in this key area of epigenetics,” Micallef said in a statement.  Volition has filed patent applications on the Nu.Q tools, in addition to its bead-based Nu.Q assay format, to decipher the epigenetic and environmental profiles of cancer nucleosomes. The platform detects and measures circulating nucleosomes and transcription factors with potential to be tissue specific, and therefore cancer specific. If successful, the platform could result in a simple blood test for multiple cancers.  The biotech firm is using these tools to expand diagnostic developments that focus on circulating DNA fragment analysis, to a broader and potentially more powerful investigation of the epigenetic status of a patient's circulating chromosome fragments, in addition to its ongoing work with its assay-based format in a range of cancers.  Volition's research and development activities are centered in Belgium, with additional offices in Texas, London and Singapore.  Contact Angela at [email protected] Follow her on Twitter @AHarmantas

Recent related videos from verified sources

New York's Battle Over Ventilators [Video]

New York's Battle Over Ventilators

New York's Battle Over Ventilators. Hannah Buehler reports.

Credit: WKBW Buffalo     Duration: 02:46Published
Stream New Music From Drake, Frank Ocean, Sam Hunt, Troye Sivan & More | Billboard News [Video]

Stream New Music From Drake, Frank Ocean, Sam Hunt, Troye Sivan & More | Billboard News

Drake’s got a new song and it’s already a TikTok dance challenge, Frank Ocean drops two new tracks on streaming platforms and Steve Aoki has us up and dancing on this fine Friday! Billboard News..

Credit: Billboard News     Duration: 03:42Published

Recent related news from verified sources

ImmunoPrecise Antibodies names Yasmina Noubia Abdiche as chief scientific officer

ImmunoPrecise Antibodies Ltd (OTCMKTS:IPATF) (CVE:IPA), the antibody discovery specialist, has appointed Dr Yasmina Noubia Abdiche as the group's chief...
Proactive Investors

MGX Minerals reveals encouraging results from research collaboration

MGX Minerals Inc (CSE:XMG) (OTCPINK:MGXMF) said it has completed a collaborative project looking at the long-term stability of nanostructure silicon fabricated...
Proactive Investors

You Might Like

Tweets about this

Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2020 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.